Lung Cancer

Oncology Solutions

Lung Cancer is the leading cause of cancer deaths around the world, causing more deaths than prostate, breast and colon cancer combined.1 Only 18.5 percent of patients will survive five or more years after being diagnosed with lung cancer.2
Reinforcing the National Lung Cancer Screening Trail’s (NLST)3, the Nelson study provided promising new results that annual screening of high risk patients using low dose CT had a 26 percent mortality reduction in the male trial.4,5 GE Healthcare provides high quality CT scanners for the new low dose lung cancer screening option.6

The Patient Journey

  • VolumeRAD™ Digital Tomosynthesis

    Volumetric images at a low dose. Right here, right now.

  • Revolution™ Apex Platform

    A cutting-edge platform with best-in-class technology and unparalleled clinical capabilities

  • Computed Tomography

    Your need for quality patient care at low dose with greater productivity and affordability is more important than ever.  That’s why we design CT syst...

  • Advantage 4D

    Efficient and accurate visualization and assessment of respiratory induced motion with fast 4D image reconstruction.

  • OEC Elite CFD

    Mobile full size c-arm offers stunning image clarity and detail at low dose with enhancements for an easy and efficient experience.

  • VolumeRAD™ Digital Tomosynthesis

    Volumetric images at a low dose. Right here, right now.

The latest in Oncology


INSIGHTS
1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864624/#R1
2. Lung and Bronchus Cancer - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/lungb.html
3. National Cancer Institute. (2018). National Lung Screening Trial. [online] Available at: https://www.cancer.gov/types/lung/research/nlst [Accessed 5 Nov. 2018].
4. Acr.org. (2018). Nelson Lung Cancer Screening Study Confirms NLST Results. [online] Available at: https://www.acr.org/Media-Center/ACR-News-Releases/2018/Nelson-Lung-Cancer-Screening-Study-Confirms-NLST-Results [Accessed 5 Nov. 2018].
5. NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer Mortality by 26 Percent in Men [Internet]. IASLC; 2018 [cited 5 November 2018]. Available from: https://wclc2018.iaslc.org/media/2018%20WCLC%20Press%20Program%20Press%20Release%20De%20Koning%209.25%20FINAL%20.pdf
6. The FDA has cleared the following qualified GE Healthcare CT scanners to receive the new low-dose CT Lung Cancer Screening Option: RevolutionTM CT, Revolution GSI, Revolution HD, Revolution EVO, Revolution DiscoveryTM CT, Discovery CT750 HD, Discovery CT590 RT, Optima TM CT660, Optima CT540, Optima CT580, Optima CT580 W, Optima CT590 RT, LightSpeed TM Xtra, LightSpeed RT16, LightSpeed Pro32, LightSpeed VCT Select, LightSpeed VCT XT, LightSpeed VCT XTe, LightSpeed VCT, LightSpeed Pro16, LightSpeed 16 and BrightSpeed TM Elite. The following PET/CT and SPECT/CT systems that use the qualified CT systems are also eligible to receive the lung cancer screening option: Discovery IQ, Discovery PET/CT 610, Discovery PET/CT 710, Discovery CT670 with 16-slice CT and Discovery CT670 Pro.

JB02164UK